Since then, several clinical studies have shown its safe and effective use - but the pharmacuetical companies have decided not to (yet) pursue FDA-Approval (likely because each new FDA-Approval costs several million dollars to go through the process, and because there are a good deal of drugs used off-label in the way tranexamic acid is for melasma, especially when the drug has a long history of safety and efficacy, as is in this case)
All clinical decisions regarding patient eligibility, dosing, monitoring, and treatment should be made by a licensed healthcare provider based on the individual patients clinical presentation, medical history, and applicable standard of care
The mistake I see most is treating glutathione as a retinoid replacement
Swissmedic has flagged Lemon Bottle for mislabeled ingredients , highlighting potential regulatory issues
10.1016/S0891-5849(96)00338-3
Adams, J., Lauterburg, B